Colon (Large Intestine)

These ingredients are often used in alternative medicine to support colon (large intestine).

• 2'-fucosyllactoseScientific

  2'-Fucosyllactose (2'-FL) is the most abundant human milk oligosaccharide and a documented prebiotic that is fermented in the colon by beneficial bacteria including Bifidobacterium and Akkermansia muciniphila. It selectively promotes colonic microbiota favorable to intestinal health and barrier function.

• acaciaScientific

  Acacia gum's primary site of physiological activity is the colon: it resists digestion in the small intestine and is fermented distally by colonic bacteria into SCFAs, selectively feeding beneficial Bifidobacteria and Lactobacilli while inhibiting pathogens. Human in vitro and clinical data confirm its colonically targeted prebiotic effects.

• acemannanScientific

  Acemannan is a long-chain polysaccharide (mannose polymer) extracted from Aloe vera inner leaf gel, with documented immunomodulatory and mucosal protective properties in the colon. It is the primary active component of aloe gel studied for inflammatory bowel conditions.

• adzuki beanScientific

  Adzuki bean dietary fiber—both soluble and insoluble fractions—is fermented by colonic microbiota to produce SCFAs, which nourish colonocytes and regulate colonic immune responses. Animal studies show adzuki bean seed coat fiber ameliorates DSS-induced colitis markers in the colon. Fiber's role in reducing colon transit time and promoting regularity is well-established.

• agarScientific

  Agar reaches the colon largely intact after resisting small intestinal digestion, where it is fermented by specific human colonic bacteria including Bacteroides uniformis. This fermentation produces short-chain fatty acids and selectively enriches bifidobacteria and related taxa. Agar-derived oligosaccharides have demonstrated prebiotic activity in human fecal-derived fermentation systems, and the physical bulk of agar in the colon supports increased stool frequency.

• ajwainScientific

  Ajwain's antispasmodic, carminative, and antimicrobial effects act primarily on the large intestine to relieve gas, constipation, and diarrhea. Calcium channel-blocking smooth muscle relaxation (characterized in isolated gut preparations) and pathogen inhibition support these colonic effects scientifically.

• akkermansia muciniphilaScientific

  Akkermansia muciniphila is a mucin-degrading bacterium that naturally colonizes the human large intestinal mucus layer. Scientifically, it is associated with maintenance of gut barrier integrity, reduction of colonic inflammation, and improved metabolic health. Its abundance is inversely correlated with IBD, obesity, and type 2 diabetes.

• ALA (alpha-linolenic acid)Scientific

  ALA reduces colonic inflammation in animal models of IBD and suppresses pro-inflammatory gene expression in human colonic epithelial cells. It also supports colonic mucosal barrier integrity and modulates gut microbiota.

• alginic acidScientific

  Alginate reaches the colon largely intact where it is fermented by specific bacteria to produce SCFAs, promotes beneficial microbial species, and exerts anti-inflammatory effects relevant to ulcerative colitis. Evidence comes from human microbiome studies, animal IBD models, and a registered human clinical trial protocol.

• allicinScientific

  Allicin (diallyl thiosulfinate) is the primary bioactive organosulfur compound produced from raw garlic with documented broad-spectrum antimicrobial activity against colonic pathogens including H. pylori, E. coli O157:H7, and C. difficile. Clinical studies support its role in reducing intestinal infections and inflammatory bowel conditions.

• allyl sulfideScientific

  Allyl sulfide is a garlic-derived organosulfur compound with documented colorectal cancer chemopreventive effects and antimicrobial activity against colonic pathogens. It works alongside allicin, DADS, and DATS as part of garlic's documented beneficial effects on the large intestine.

• almondScientific

  The colon is the primary site of almond's prebiotic effects. Clinical trials demonstrate enrichment of beneficial colonic bacteria, increased SCFA (particularly butyrate) production, suppression of pathogenic bacteria, and modifications of bacterial enzyme activities that reduce potentially harmful metabolite production. Almond cell wall lipids reach the colon intact, serving as fermentable substrate.

• aloe veraScientific

  Aloe vera latex contains anthraquinone glycosides (barbaloin, isobarbaloin) that are metabolized in the large intestine to aloe-emodin-anthrone, a cathartic agent that inhibits colonic water absorption and stimulates secretion. The gel form has shown efficacy for ulcerative colitis in clinical trials. Traditional and scientific use for colon health is well documented.

• aloinScientific

  Aloin (barbaloin) is the principal anthraquinone glycoside of aloe vera latex, acting as a prodrug laxative specifically in the large intestine. Colonic bacteria convert it to aloe-emodin-anthrone, which inhibits water absorption and stimulates fluid secretion in the colon.

• andrographisScientific

  Andrographis (Andrographis paniculata) and its primary constituent andrographolide have multiple clinical RCTs demonstrating efficacy in ulcerative colitis and diarrheal illness. The plant specifically targets the large intestine through NF-κB inhibition, reduction of mucosal pro-inflammatory cytokines, and antimicrobial activity.

• andrographolideScientific

  Andrographolide is the primary bioactive diterpene lactone of Andrographis paniculata with multiple RCTs demonstrating efficacy specifically in ulcerative colitis (a large intestinal disease) at doses of 1200–1800mg/day. It inhibits NF-κB and reduces mucosal pro-inflammatory cytokines in the colon.

• anthraquinoneScientific

  Anthraquinones are the chemical class responsible for the laxative action of senna, cascara, rhubarb, and aloe on the large intestine. They are prodrugs metabolized by colonic flora into active anthrone metabolites that stimulate peristalsis and inhibit water/electrolyte reabsorption from the colon.

• apigeninScientific

  Apigenin is a flavone abundant in chamomile and parsley with documented anti-inflammatory, antispasmodic, and anti-cancer effects in the colon. It reaches the large intestine where it is metabolized by colonic bacteria and inhibits NF-κB, reduces colonic inflammation, and induces apoptosis in colorectal cancer cells.

• appleScientific

  Apple pectin and polyphenols are prebiotics that promote beneficial colonic bacteria and SCFA production. Apple polyphenols reaching the colon intact undergo bacterial biotransformation into bioavailable metabolites that reduce colonic inflammation and support barrier integrity.

• apple cider vinegarScientific

  Animal evidence shows ACV remodels cecal microbiota and metabolites, enriching beneficial taxa and reversing high-fat-diet dysbiosis. ACV's pectin acts as a prebiotic fiber in the large intestine. No human RCTs with colonic endpoints (microbiome, transit, mucosal health) have been published.

• apricotScientific

  Apricot's dietary fiber, including soluble pectin and insoluble fractions, supports colon health through prebiotic fermentation, production of short-chain fatty acids (SCFAs), stool bulk formation, and promotion of regular transit. Apricot's sorbitol content also softens stool osmotically. Epidemiological literature consistently associates high fruit and fiber intake with reduced colorectal cancer risk.

• arabinogalactanScientific

  Arabinogalactan (from larch bark, Larix occidentalis) is a highly branched prebiotic polysaccharide fermented in the colon by beneficial bacteria. Multiple human studies confirm it increases short-chain fatty acid production, enhances Bifidobacterium growth, and supports colonic immune function.

• asparagusScientific

  Asparagus' inulin and FOS undergo fermentation specifically in the colon, producing SCFAs that lower colonic pH, strengthen the gut barrier, inhibit pathogenic bacteria, and support beneficial colonocyte metabolism. Human gut simulator studies confirm asparagus powder modulates microbial communities in the colonic environment. The defecation-promoting effect documented in pharmacological reviews also directly involves the colon.

• aspergillusScientific

  Aspergillus-derived enzyme preparations and fermentation products exert their microbiome-modulating effects predominantly in the cecum and large intestine, where bifidogenic increases in Bifidobacterium and Lactobacillus have been measured in preclinical studies. A. oryzae-derived FOS and GOS produced by Aspergillus-derived beta-galactosidase also undergo fermentation in the colon, generating short-chain fatty acids.

• assam indigoScientific

  The colon is the primary organ target of Qingdai (S. cusia-derived) clinical evidence. Multiple RCTs and prospective studies confirm mucosal healing, remission induction, and cytokine normalization in the colonic mucosa of UC patients treated with Qingdai preparations.

• bacillus clausiiScientific

  B. clausii transiently colonizes the colon, where it reduces gut dysbiosis, modulates microbial community composition, and suppresses colonic inflammation. Preclinical evidence shows it suppresses NF-κB and NLRP3 inflammasome pathways in the colon in ulcerative colitis models. Clinical benefit for colonic diarrhea and microbial restoration has been demonstrated.

• bacillus coagulansScientific

  Bacillus coagulans is a spore-forming probiotic bacterium with multiple RCTs demonstrating benefits for IBS, constipation, and diarrhea. Its spores survive gastric transit and germinate in the large intestine, producing lactic acid and modulating the colonic microbiome.

• bacillus subtilisScientific

  Bacillus subtilis is a spore-forming probiotic with documented colonic microbiome-modulating effects, producing antimicrobial compounds (iturin, fengycin) in the GI tract. Clinical and in vitro studies support its role in supporting large intestinal health and inhibiting enteropathogens.

• baicaleinScientific

  Baicalein is the aglycone of baicalin, produced by colonic bacterial deconjugation in the large intestine. It demonstrates potent NF-κB inhibition, anti-inflammatory effects in colonic mucosa, and anti-cancer activity against colorectal cancer cells in multiple in vitro and animal studies.

• baicalinScientific

  Baicalin is a flavone glucuronide from Scutellaria baicalensis (Huang Qin) with documented anti-inflammatory effects in the colon and clinical studies showing benefit in UC. Colonic bacteria deconjugate baicalin to the more bioactive baicalein, which suppresses NF-κB and reduces colonic inflammation.

• baikal skullcapScientific

  S. baicalensis has direct colon-relevant evidence including protection against DSS-induced colonic ulceration in animal models, traditional use for dysentery and large intestinal conditions, clinical data from China for acute enteritis and dysentery, and regulation of intestinal microbiota and barrier integrity.

• bambooScientific

  Bamboo shoot dietary fiber is fermented by colonic microbiota to produce SCFAs (butyrate, propionate, acetate), which nourish colonocytes, regulate intestinal barrier proteins, and reduce colonic inflammation. Multiple PMC-indexed studies show bamboo fiber modulates colonic microbiota beneficially and reduces DSS-induced colitis severity.

• bananaScientific

  Banana resistant starch (RS2) is fermented by colonic microbiota to produce short-chain fatty acids including butyrate, which nourish colonocytes and support colonic barrier integrity. Multiple RCTs confirm green banana prebiotic effects, increasing Bifidobacterium and Akkermansia colonization. Banana fiber reduces colonic transit time dysfunction and improves stool consistency.

• baobabScientific

  Baobab's prebiotic fiber is fermented in the colon, stimulating SCFA production and selectively promoting health-associated bacterial genera. In vitro fecal fermentation studies show baobab boosted acetate, propionate, and butyrate production; a SHIME® simulator study confirmed increased Bifidobacteriaceae, Faecalibacterium prausnitzii, and Akkermansiaceae in both proximal and distal colon compartments. The ongoing Cape Town RCT will measure gut microbiota composition as a secondary in vivo human endpoint.

• barberryScientific

  Berberine from barberry protects the colonic mucosal barrier, modulates colonic microbiota, and reduces colonic inflammation in preclinical models. Registered clinical trials are investigating berberine for ulcerative colitis (colon) remission maintenance.

• barleyScientific

  Barley fiber (β-glucan, resistant starch, fructan) is fermented in the colon by protective bacteria, producing butyrate that fuels colonocytes and supports mucosal integrity. GBF has been clinically shown to reduce colonic mucosal inflammation in ulcerative colitis and to increase luminal butyrate.

• berberineScientific

  Berberine is an isoquinoline alkaloid with multiple RCTs demonstrating efficacy for diarrhea-predominant IBS, ulcerative colitis, and modulation of the colonic microbiome. A meta-analysis of 28 UC animal studies confirmed significant reduction in disease activity index, colon length preservation, and histological score improvement.

• beta-glucanScientific

  Beta-glucan (from oat, barley, or yeast) is a soluble prebiotic fiber fermented by colonic bacteria into short-chain fatty acids including butyrate. Multiple clinical studies confirm it improves colonic transit, promotes Bifidobacterium growth, and supports the colonic epithelial barrier.

• bifidobacteriaScientific

  Bifidobacteria are native inhabitants of the human large intestine, fermenting prebiotic fibers into health-promoting short-chain fatty acids. Multiple RCTs and systematic reviews confirm their beneficial roles in managing constipation, diarrhea, IBS, and ulcerative colitis when supplemented as probiotics.

• bifidobacteriumScientific

  Bifidobacterium is a well-characterized probiotic genus residing predominantly in the large intestine. Multiple RCTs confirm benefits in constipation, diarrhea, IBS, and inflammatory bowel disease. They ferment prebiotic fibers in the colon to produce beneficial short-chain fatty acids.

• bifidobacterium adolescentisScientific

  Bifidobacterium adolescentis is a native large intestinal bacterium with documented prebiotic fiber fermentation capacity. It is specifically responsive to inulin-type fructan supplementation, showing significant increases in RCTs of prebiotic intervention for gut microbiota modulation.

• bifidobacterium animalisScientific

  Bifidobacterium animalis (particularly subsp. lactis) is extensively clinically studied for its colon-targeted effects, including accelerating colonic transit time and improving gastrointestinal symptoms in constipation and IBS. It colonizes the large intestine and produces beneficial short-chain fatty acids.

• bifidobacterium bifidumScientific

  Bifidobacterium bifidum is a native colonizer of the human large intestine with documented ability to inhibit intestinal pathogens, support the colonic epithelial barrier, and modulate mucosal immune responses. Clinical studies support its use in IBD management and constipation.

• bifidobacterium breveScientific

  Bifidobacterium breve is a clinically studied large intestinal probiotic with documented anti-inflammatory properties, ability to inhibit colonic pathogens, and support for gut barrier integrity. In vitro and clinical studies confirm benefits in IBD and gut dysbiosis.

• bifidobacterium infantisScientific

  Bifidobacterium infantis is a well-documented colonic probiotic with the most extensive genetic machinery for fermenting human milk oligosaccharides (HMOs) in the large intestine. A landmark RCT (n=362) found B. infantis 35624 significantly reduced IBS symptom scores vs. placebo.

• bifidobacterium lactisScientific

  Bifidobacterium lactis (B. animalis subsp. lactis) is one of the most clinically studied Bifidobacterium species for colon health. RCTs demonstrate improvements in colonic transit time, stool frequency, and IBS symptom scores. It colonizes the large intestine and produces beneficial fermentation metabolites.

• bifidobacterium longumScientific

  Bifidobacterium longum is a predominant large intestinal bacterium with well-documented benefits for constipation, IBS, and inflammatory bowel disease. In vitro and clinical studies confirm its anti-inflammatory effects, barrier protection, and pathogen inhibition in the colon.

• bile saltScientific

  Approximately 5% of bile salts escape ileal reabsorption and enter the colon, where gut bacteria convert them to secondary bile acids (deoxycholic acid and lithocholic acid) via deconjugation and dehydroxylation. These secondary bile acids have potent secretory and motility-stimulating effects on the colonic mucosa. Excess bile acids in the colon cause watery diarrhea (bile acid malabsorption/diarrhea), while secondary bile acids also modulate TGR5 signaling relevant to GLP-1 and colonic immunity.

• black teaScientific

  Black tea polyphenols are extensively metabolized in the colon, where they modulate microbiota composition with prebiotic-like effects and exert anti-inflammatory actions on the colonic epithelium. Animal models of colitis show reduced inflammation and improved intestinal barrier integrity with black tea extract.

• blackberryScientific

  Blackberry fiber and polyphenols support colonic health through prebiotic fermentation, microbiota modulation, and anti-inflammatory effects on colonic epithelium. Blackberry ellagic acid attenuated DSS-induced colitis in mouse models by modulating gut microbiota and blocking NF-κB/MAPK inflammatory pathways. Blackberry's insoluble and soluble fiber promote healthy transit and colonic fermentation.

• blueberryScientific

  The colon is the primary site of blueberry anthocyanin metabolism by gut bacteria. Blueberry polyphenols act as prebiotics in the colon, shifting microbial composition toward SCFA-producing taxa and generating bioactive phenolic metabolites that drive systemic effects.

• boswelliaScientific

  Boswellia (Boswellia serrata) and its active boswellic acids have multiple clinical RCTs demonstrating efficacy specifically in Crohn's disease and ulcerative colitis (large intestinal inflammatory conditions). AKBA (acetyl-11-keto-β-boswellic acid) inhibits 5-LOX and NF-κB in colonic mucosa.

• boswellic acidScientific

  Boswellic acids (particularly AKBA) are the primary bioactive anti-inflammatory compounds of Boswellia serrata resin with multiple RCT evidence for efficacy in Crohn's disease and collagenous colitis (large intestinal conditions) through selective 5-LOX and NF-κB inhibition.

• broccoliScientific

  Broccoli fiber serves as a prebiotic substrate for colonic bacteria, supporting SCFA production and colonic barrier integrity. Sulforaphane and other isothiocyanates reach the colon and are bioactivated there, with established chemopreventive activity against colorectal cancer in observational and experimental studies.

• bromelainScientific

  Bromelain has demonstrated anti-inflammatory effects in the colon in both animal and clinical studies, most directly in ulcerative colitis. It suppresses NF-κB, blocks TNF-α receptors, and reduces colonic pro-inflammatory cytokine production. A 2025 RCT in ulcerative colitis and preclinical studies in IL-10-deficient mice with IBD directly support its role in the large intestine.

• brussel sproutsScientific

  Brussels sprouts fermentable fiber feeds colonic microbiota and generates butyrate, which nourishes the colonic epithelium. Human trials confirm that one week of Brussels sprouts consumption raises colonic mucosal GST-alpha and GST-pi by 15–30%, enhancing local detoxification. Epidemiological data link cruciferous vegetable consumption to reduced colorectal cancer risk.

• buckthornScientific

  The colon is the primary site of buckthorn's pharmacological action. Anthraquinone glycosides are converted by colonic bacteria into active anthrone metabolites, which directly stimulate propulsive colonic contractions and inhibit water reabsorption, producing the laxative effect. This mechanism is documented in the Commission E monograph, ESCOP, and peer-reviewed pharmacological literature.

• burdockScientific

  Burdock root's inulin content (up to 50% of dry weight) acts as a prebiotic in the colon, selectively enriching beneficial bacteria and producing SCFAs. An open-label RCT (Mizuki et al., Scientific Reports, 2019) found burdock tea significantly reduced the recurrence of colonic diverticulitis and diverticular bleeding vs. control. Burdock inulin studies confirm modulation of colon microbiota composition.

• butyrate triglycerideScientific

  Butyrate triglyceride (tributyrin) is a prodrug form of butyric acid that delivers butyrate to the colon after hydrolysis by intestinal lipases. It is studied as a colon-targeted means of delivering the primary colonocyte fuel and anti-inflammatory SCFA to the large intestinal mucosa.

• butyric acidScientific

  Butyric acid is a short-chain fatty acid produced by colonic fermentation of dietary fiber and the primary energy source for colonocytes. It maintains the integrity of the colonic epithelium, regulates colonocyte proliferation and apoptosis, and exerts anti-inflammatory effects in the colon relevant to IBS, ulcerative colitis, and colorectal cancer prevention.

• cabbageScientific

  Cabbage fiber is fermented by colonic microbiota into SCFAs, which are the primary energy substrate for colonocytes and support colon health. Red cabbage juice modulates colonic microbiota, enriches SCFA-producing bacteria, and improves tight junction proteins in mouse colitis models. Fermented cabbage provides Lactobacillus bacteria that modulate colon microbiota in human studies.

• cabbage leafScientific

  Cabbage is high in insoluble dietary fiber that promotes intestinal transit and stool bulk in the colon, with traditional use for constipation. Glucosinolate-derived metabolites regulate intestinal microbiota and reduce inflammatory cytokines in the colon, with PMC-reviewed evidence (2024) for their attenuation of inflammatory bowel disease. Traditional use of cabbage juice as a remedy for constipation is documented across European, Roman, and Greek medicine.

• caprylic acidScientific

  Caprylic acid is rapidly absorbed in the proximal small intestine and may not reach the colon in significant quantities when taken orally. However, it is produced endogenously by colonic microbiota as a fermentation metabolite and is measurably depleted in IBD patients' stool. Its colonic presence is therefore microbiome-mediated rather than primarily dietary.

• carawayScientific

  Caraway oil applied topically over the abdomen was tested in a randomized controlled trial for IBS symptom relief, implicating colonic smooth muscle modulation. Animal studies show immunomodulatory caraway effects reducing colon tissue damage in inflammatory bowel disease models. The carminative action reducing colonic gas is its best-established digestive effect.

• carrotScientific

  Carrot fiber fermented by colonic bacteria produces SCFAs (acetate, propionate, butyrate) that fuel colonocytes and support colon mucosal health. Carrot polyacetylenes downregulate colonic inflammatory gene expression. These effects are documented in in vitro, animal, and simulated-gut studies with mechanistic human data.

• caryophylleneScientific

  The colon is the primary intestinal target organ for BCP due to high PPARγ and CB2 receptor expression. Multiple studies confirm BCP reduces colonic inflammation, damage, and cytokine expression in DSS-induced colitis models.

• cascara sagradaScientific

  Cascara sagrada (Rhamnus purshiana bark) is an anthraquinone-based stimulant laxative with specific activity on the large intestine. Its active cascarosides act locally to promote colonic peristalsis and inhibit water/electrolyte reabsorption from the colon. It has been used by Native Americans for centuries and was accepted into Western medical practice in the 19th century.

• cascarosideScientific

  Cascarosides are the principal active anthraquinone glycosides of cascara sagrada bark, exerting their laxative action specifically in the large intestine by stimulating peristalsis and inhibiting electrolyte and water reabsorption from the colon. They are structurally related to sennosides.

• catechinsScientific

  Catechins that reach the colon are metabolized by gut bacteria into bioactive phenolic acids, and they selectively modulate colonic microbiota by promoting beneficial anaerobes and suppressing pathogens. These effects are relevant to IBD, colorectal health, and systemic metabolic outcomes.

• catjang cowpeaScientific

  Cowpea polyphenols protect colonic cells from inflammatory and oxidative challenge. Dietary fiber from cowpea feeds beneficial bacteria and supports butyrate production in the colon. An in vitro study showed modulation of microRNA-126 in colonic myofibroblasts, suggesting epigenetic anti-inflammatory effects.

• cauliflowerScientific

  Cauliflower's dietary fiber feeds the colonic microbiome, promoting SCFA production and microbiome diversity. Its glucosinolate metabolites reduce colonic inflammation and may inhibit colorectal cancer cell proliferation. Epidemiological data associates crucifer intake with reduced colorectal cancer risk.

• cellulaseScientific

  Undigested cellulose that reaches the colon is the primary substrate for cellulase-producing bacteria, which produce SCFAs critical for colonocyte health. A 2024 Science study identified ruminococcal bacteria in the human colon producing functional cellulase complexes. Research in pig models demonstrates that cellulase treatment increases colonic SCFA production and shifts microbiota composition. Supplemental cellulase that is not active in the small intestine may also modulate the colonic substrate pool.

• chia seedScientific

  Chia seeds (Salvia hispanica) are rich in soluble mucilaginous fiber that forms a gel in the large intestine, supporting stool formation, colonic transit, and serving as a prebiotic substrate for beneficial colonic bacteria. Clinical studies confirm benefits for constipation and bowel regularity.

• chickpea proteinScientific

  Chickpea fibre and protein ferment in the colon to produce butyrate and other SCFAs that nourish colonocytes, support epithelial barrier integrity, and reduce inflammation. Daily chickpea consumption is associated with reduced colorectal cancer risk in observational data. Clinical trials confirm improved bowel function including stool regularity with chickpea supplementation.

• chicoryScientific

  Chicory root (Cichorium intybus) is the primary commercial source of inulin-type fructans, the only prebiotic fiber with an EFSA-approved health claim: 'Chicory inulin contributes to normal bowel function by increasing stool frequency.' Multiple RCTs confirm its bifidogenic and laxation effects in the large intestine.

• chlorellaScientific

  Clinical studies, though limited, have examined chlorella for ulcerative colitis and IBS—conditions of the large intestine. Mechanistically, chlorella's fiber, prebiotic content, and anti-inflammatory chlorophyll directly act in the colon.

• chlorophyllinScientific

  Chlorophyllin acts within the colon to modulate gut microbiota composition, attenuate colonic inflammation in IBD models, and intercept dietary carcinogens before they cause colonic DNA damage. Animal studies show significant downregulation of Firmicutes and upregulation of Bacteroidetes, and attenuation of colitis markers including epithelial damage and inflammatory cell infiltration. The Linus Pauling Institute notes a caveat that in rat studies, chlorophyllin suppressed liver cancer while increasing colon cancer risk, underscoring complexity.

• chokeberryScientific

  The colon is the primary site of chokeberry polyphenol bioavailability, where unabsorbed anthocyanins and proanthocyanidins are metabolised by gut bacteria. Human RCTs document increased butyrate-producing bacteria in the colon following chokeberry supplementation. Animal studies show promise against colon cancer cells. The gut microbiome-modulating effects are clinically significant.

• citrus pectinScientific

  Citrus pectin is a soluble prebiotic fiber from citrus fruit peel that ferments in the colon to produce short-chain fatty acids and promotes beneficial bacteria. Modified citrus pectin has been clinically studied for its ability to bind toxins and heavy metals in the large intestine and for colorectal cancer prevention.

• clostridium butyricumScientific

  Clostridium butyricum is a spore-forming probiotic bacterium that is a major producer of butyric acid in the large intestine. Clinical trials in Japan and Korea support its use for IBS, ulcerative colitis, and necrotizing enterocolitis prevention, with mechanisms centered on colonic butyrate production and mucosal protection.

• coixScientific

  Coix seed polysaccharides and extracts modulate gut microbiota composition and improve intestinal barrier function, with specific effects on the colon microbiome demonstrating increased diversity and SCFA-producing bacteria. Coix sprouts have also been studied for anti-colon cancer activity.

• collardScientific

  Collard greens' fiber is fermented in the colon to produce butyrate and other SCFAs that nourish colonocytes and maintain mucosal barrier integrity. Glucosinolate-derived isothiocyanates and indole-3-carbinol have demonstrated anti-tumor effects in colon cancer cell lines. The National Cancer Institute recognizes cruciferous glucosinolates as chemoprotective via inhibiting colon cancer growth in animal models.

• colostrumScientific

  Bovine colostrum contains immunoglobulins (IgG, IgA), growth factors (IGF-1, TGF-β), and lactoferrin that support intestinal mucosal integrity and modulate the colonic immune environment. Multiple RCTs demonstrate benefits for diarrhea prevention, bowel permeability reduction, and colonic mucosal healing.

• cornScientific

  Soluble corn fiber is fermented in the colon by gut bacteria, producing SCFAs that benefit colonic health, support immunoregulation, and improve intestinal barrier integrity. Human RCT evidence confirms SCF's prebiotic effects and colonic fermentation profile. Corn fiber is scientifically well-characterized as a colonic fermentation substrate.

• curcuminScientific

  Curcumin demonstrates significant anti-inflammatory activity in the large intestine, with multiple human RCTs showing benefit as adjuvant therapy in ulcerative colitis and IBS. Mechanisms include NF-κB inhibition, MAPK suppression, and reduction of pro-inflammatory cytokines in colonic mucosa.

• curcuminoidScientific

  Curcuminoids (curcumin, demethoxycurcumin, bisdemethoxycurcumin) are the collective bioactive polyphenols of turmeric with documented anti-inflammatory effects in the large intestine, studied clinically in ulcerative colitis and IBS. Their mechanisms include NF-κB inhibition and pro-inflammatory cytokine suppression in colonic mucosa.

• D-glucarateScientific

  The colon is the primary site of D-glucarate's pharmacological action: its active metabolite D-glucaro-1,4-lactone inhibits beta-glucuronidase produced by colonic bacteria. Human studies show fecal beta-glucuronidase is significantly elevated in colon cancer patients, and D-saccharic acid 1,4-lactone inhibited this enzyme in both cancer patients and healthy controls.

• DADS (diallyl disulfide)Scientific

  Diallyl Disulfide (DADS) is an organosulfur compound from garlic with documented anticancer effects on colorectal cancer cells, antimicrobial activity against H. pylori and C. difficile, and anti-inflammatory effects in the colon through NF-κB inhibition and HDAC inhibition.

• DATS (diallyl trisulfide)Scientific

  Diallyl Trisulfide (DATS) is a garlic-derived organosulfur compound with documented pro-apoptotic effects on colorectal cancer cells, antimicrobial activity against H. pylori and C. difficile, and anti-inflammatory effects in the colon. It is considered more potent than DADS for colorectal cancer cell inhibition.

• delta-tocopherolScientific

  Delta-tocopherol demonstrated the strongest inhibitory effect among tocopherol forms in an azoxymethane-induced rat colon carcinogenesis model, decreasing aberrant crypt foci (ACF) by 62% versus control. It inhibits COX-2, reduces prostaglandin E2, and prevents loss of differentiation receptors in colon cancer cells. Mixed γ-tocopherol-rich tocopherol diets containing δ-tocopherol inhibit colon inflammation and carcinogenesis in multiple rodent models.

• docosahexaenoic acidScientific

  DHA exerts anti-inflammatory and mucosal protective effects in the colon, reducing pro-inflammatory cytokines, oxidative stress, and improving tight junction barrier function in experimental colitis. A large European prospective cohort found high dietary DHA inversely associated with Crohn's disease incidence. DHA modulates colonic gut microbiota composition.

• dulse leafScientific

  Dulse's xylan polysaccharides reach the colon intact, where they function as fermentation substrate for beneficial bacteria, increasing SCFA production. This was demonstrated in a 2023 mouse study in which Palmaria palmata extract expanded Lactobacillus populations and increased beneficial microbial communities. SCFAs produced locally in the colon support colonocyte energy supply and intestinal barrier function.

• ellagic acidScientific

  Ellagic acid is a polyphenol from pomegranate, walnuts, and berries that is metabolized in the large intestine by colonic bacteria into urolithins (urolithin A, B). Urolithins have well-documented anti-inflammatory and anti-cancer effects specifically in the colon, with clinical trial evidence.

• enterococcusScientific

  Enterococcus faecium SF68 and similar probiotic strains have been clinically evaluated for diarrhea and IBS management in the large intestine. Multiple RCTs and systematic reviews support their use for antibiotic-associated diarrhea and bowel symptom management, particularly in combination probiotic preparations.

• EPA (eicosapentaenoic acid)Scientific

  EPA exerts direct anti-inflammatory effects on the colonic mucosa. In ulcerative colitis, EPA-FFA reduced fecal calprotectin, improved endoscopic and histological inflammation scores, promoted goblet cell differentiation, and modulated the gut microbiota in placebo-controlled human trials. Mendelian randomization data further support a causal protective role of EPA on IBD risk.

• fava beanScientific

  Fava beans' resistant starch, soluble fiber, and galacto-oligosaccharides are fermented in the colon by beneficial bacteria into short-chain fatty acids including butyrate, the primary energy source for colonocytes. This fermentation promotes microbiome diversity, supports mucosal integrity, and promotes bowel regularity.

• fennelScientific

  Fennel seed extract directly modulates colonic epithelial barrier function and the STAT/JAK inflammatory pathway in vitro, and has clinical evidence supporting symptom reduction in IBS. Traditional use as a carminative targets gas and colonic motility.

• ferula assafoetidaScientific

  Asafoetida exerts antispasmodic, antimicrobial, and anti-inflammatory effects on the colon relevant to IBS, colitis, and flatulence. A rat ulcerative colitis model showed positive effects from asafoetida encapsulated in turmeric nanofibers, and carminative action on the colon is foundational to its Ayurvedic use.

• fisetinScientific

  Fisetin is a dietary flavonoid with documented anti-inflammatory and anti-cancer effects in the colon, inhibiting colorectal cancer cell proliferation and exerting senolytic activity. It is fermented in the colon to bioactive metabolites by colonic bacteria.

• fish oilScientific

  Fish oil omega-3s modulate colonic inflammation and may reduce colorectal cancer risk. Animal models of colitis show fish oil decreases colonic damage and inflammation. RCTs in inflammatory bowel disease (IBD) show fish oil supplementation modulates inflammatory mediators in the colonic mucosa, with some benefit in ulcerative colitis. ConsumerLab notes recent evidence that fish oil may reduce colorectal cancer risk in certain people.

• flaxseedScientific

  Flaxseed (Linum usitatissimum) provides both soluble fiber (mucilage) and insoluble fiber that support large intestinal health through stool bulking, colonic transit acceleration, and prebiotic effects. Clinical trials confirm benefits for constipation and IBS.

• FOS (fructooligosaccharides)Scientific

  Fructooligosaccharides (FOS) are prebiotic fibers fermented selectively by colonic bacteria — especially Bifidobacterium — producing short-chain fatty acids (SCFAs) that nourish colonocytes and regulate bowel function. EFSA has approved a health claim for chicory inulin/FOS for improving bowel function by increasing stool frequency.

• fucoidanScientific

  Fucoidan is a sulfated polysaccharide from brown seaweeds with documented anti-inflammatory effects in the colon, prebiotic potential, and emerging clinical evidence for benefit in colorectal cancer patients and IBD. It modulates colonic microbiota and reduces mucosal inflammatory cytokines.

• fulvic acidScientific

  Fulvic acid acts as a selective prebiotic in the colon, stimulating Lactobacillus and Akkermansia muciniphila growth. Animal studies show improved colonic microbial community structure. A human clinical trial with related humic acid showed increased microbiota concentration over 45 days.

• galactosidaseScientific

  The colon is the site where alpha-galactosidase exerts its indirect but critical effect: by hydrolyzing oligosaccharides in the small intestine, the enzyme prevents undigested carbohydrates from reaching the colon where they would be fermented by bacteria to produce hydrogen gas and short-chain fatty acids. Reduction in breath hydrogen—a direct measure of colonic fermentation—is a validated endpoint in multiple RCTs.

• garbanzo beanScientific

  The colon is the primary site of garbanzo bean fiber fermentation, where prebiotic carbohydrates (resistant starch, oligosaccharides) are converted to SCFAs by resident microbiota. Butyrate produced from chickpea fermentation induces apoptosis in colon cancer cells and supports colonocyte energy metabolism. Chickpea consumption is associated with modulation of colon microbiome, enhanced mucosal barrier integrity, and reduced colorectal cancer risk markers.

• garlicScientific

  Garlic (Allium sativum) has documented prebiotic effects in the large intestine through fructooligosaccharide content, and antimicrobial effects via allicin and related thiosulfinates against colonic pathogens. Clinical studies confirm garlic promotes beneficial colonic microbiota and has anti-inflammatory effects relevant to colorectal cancer prevention.

• gingerScientific

  Ginger (Zingiber officinale) has multiple RCTs confirming its prokinetic effects on GI motility, including acceleration of gastric emptying and colonic transit. It reduces nausea, vomiting, and GI symptoms through 5-HT3 receptor antagonism and modulation of GI smooth muscle, with documented effects in the large intestine.

• glucomannanScientific

  Glucomannan (konjac flour, Amorphophallus konjac) is a viscous, gel-forming dietary fiber with strong evidence from multiple RCTs for improving constipation, increasing stool frequency, and lowering colonic transit time. It is classified as a bulk-forming laxative and prebiotic.

• green teaScientific

  Green tea catechins favorably modulate the colonic microbiota in human trials, increasing Bifidobacteria and improving gut barrier function. Epidemiological studies report an inverse relationship between green tea consumption and colorectal cancer risk. A randomized clinical phase II trial demonstrated prevention of colorectal adenoma recurrence with EGCG, and EGCG has been shown to inhibit tumor growth and angiogenesis in human colon carcinoma models.

• hemicellulaseScientific

  Hemicellulase reduces the quantity of undigested hemicellulose reaching the colon, thereby decreasing the substrate available for gas-producing bacterial fermentation. The soluble oligosaccharides generated by hemicellulase activity function as prebiotics in the colon, selectively feeding beneficial Bifidobacterium and Lactobacillus populations. Published research confirms hemicellulose-derived oligosaccharides modulate colonic microbiota diversity and SCFA production.

• holarrhena antidysentericaScientific

  Preclinical colitis models and the randomized clinical trial in ulcerative colitis (PMC5255966) directly demonstrate H. antidysenterica activity in the colon. Biomarkers of colonic inflammation and oxidative stress (MDA, SOD, GSH, NO) were significantly improved in DNBS rat colitis experiments.

• honeyScientific

  Honey's non-digestible oligosaccharides reach the colon intact, where they are fermented by beneficial microbiota to produce short-chain fatty acids (SCFAs). A 2022 Frontiers in Nutrition review (PMC9367972) documents growing evidence that honey has prebiotic capability to promote beneficial colonic bacteria including bifidobacteria and lactobacilli.

• honeysuckleScientific

  Preclinical studies show honeysuckle nanovesicles reduce colonic inflammation, repair intestinal barrier integrity, and modulate colonic microbiota including SCFA levels and bile acid metabolism in DSS-induced UC mice. Honeysuckle MIR2911 directly regulates colonic bacteria, reducing pathogenic Escherichia-Shigella.

• immunoglobin GScientific

  SBI exerts measurable effects in the colon through anti-inflammatory cytokine reduction, microbiota modulation, and barrier integrity support. Ex vivo colonic fermentation models with human adult samples confirm SBI reduces TNF-α and CXCL10 and promotes SCFA production. Mouse colitis models show significant attenuation of colonic inflammation with oral SBI.

• indian baelScientific

  Aegle marmelos exerts direct effects on the colon demonstrated in acetic acid-induced ulcerative colitis and indomethacin-induced enterocolitis rat models, with dose-dependent reduction in colonic inflammation, macroscopic damage, mast cell degranulation, and oxidative stress markers. Traditional use of bael in colitis and dysentery is documented across Ayurvedic texts.

• indian frankincenseScientific

  The colon is among the best-evidenced target organs for Boswellia serrata. RCTs in ulcerative colitis (grade II–III) demonstrate 82% remission rates with 350 mg three times daily for 6 weeks, comparable to sulfasalazine. In vitro Caco-2 colonic cell studies demonstrate direct protection of tight junction proteins.

• indian gum arabic treeScientific

  Gum arabic preferentially ferments in the distal colon, selectively increasing beneficial bacteria and producing SCFAs. Multiple in vitro colon models and human studies confirm bifidogenic prebiotic effects. Arabic gum's fermentation occurs more distally in the colon, relevant to chronic colonic diseases.

• indigo leavesScientific

  The colon is the primary site of clinical action for indigo naturalis in IBD/UC, with multiple RCTs demonstrating mucosal healing of the colonic epithelium. Mechanistic studies show AhR-mediated IL-22 production, Th1/Th17 suppression, and gut microbiota modulation specifically in the colonic environment.

• indole-3-carbinolScientific

  I3C inhibits the growth and induces apoptosis of multiple human colorectal cancer cell lines via AhR activation, G1-phase cell cycle arrest, and upregulation of p27KIP1 and p21CIP1. AhR signaling also has documented anti-inflammatory effects in the colonic mucosa. Animal models of colon carcinogenesis yield conflicting results, with some studies showing tumor promotion at high doses. No human colorectal polyp or cancer chemoprevention RCTs have been completed.

• inulinScientific

  Inulin is a prebiotic fructan fiber that is fermented exclusively in the colon, selectively stimulating Bifidobacterium and producing short-chain fatty acids that support colonocyte health. EFSA has approved the health claim 'Chicory inulin improves bowel function' based on RCT evidence of increased stool frequency.

• isomalto-oligosaccharideScientific

  The colon is the primary site of IMO activity. Undigested IMO is fermented there by beneficial bacteria into SCFAs, increasing stool bulk, lowering colonic pH, fueling colonocytes, and improving microbiome composition. Human clinical trials confirm these colonic effects.

• jujubeScientific

  Jujube polysaccharides and extracts have consistent protective effects on the colon in multiple animal models, including IBD/colitis models (DSS, TNBS, acetic acid). Mechanisms include reduced colonic cytokine production, restored colon length, enhanced mucosal integrity, and inhibition of NF-κB/JAK1/STAT3 signaling. Prebiotic effects on colonic microbiota are also documented.

• kaleScientific

  Kale's fiber, glucosinolates, and prebiotic sugars support colon health by promoting beneficial microbiota, augmenting gut barrier tight junction proteins, and reducing pro-inflammatory bacteria. Animal studies show kale protects against DSS-induced colitis and modulates microbiota in TNBS-induced colonic inflammation. Kale consumption is associated with constipation relief.

• kefirScientific

  Kefir is a traditional fermented dairy beverage containing diverse LAB, Bifidobacterium, and yeast strains with documented clinical evidence for improving constipation, bowel transit time, and colonic microbiome composition. Multiple RCTs confirm significant improvements in stool frequency and consistency.

• kefiranScientific

  Kefiran is a branched exopolysaccharide produced by Lactobacillus kefiranofaciens in kefir grain fermentation with documented prebiotic and immunomodulatory effects in the GI tract, including promoting beneficial colonic bacteria and enhancing intestinal barrier integrity.

• kidney beansScientific

  Kidney beans deliver substantial resistant starch and fermentable fiber to the large intestine, where microbial fermentation generates butyrate and other short-chain fatty acids that nourish colonocytes, reduce inflammation, and may reduce colorectal cancer risk. Research on common beans (including red kidney beans) shows modulation of colon cell growth and stool metabolome.

• konjacScientific

  Konjac (Amorphophallus konjac) is the source of glucomannan, a proven bulk-forming prebiotic fiber with RCT evidence for constipation relief and prebiotic effects in the large intestine. It has been used in Asian traditional medicine and food for thousands of years.

• L-alanyl-L-glutamineScientific

  AG protects colonic mucosal integrity, reduces colitis-associated inflammation in the colon, suppresses colonic NF-κB and TLR4 signaling, and modulates colonic microbiota. Multiple animal colitis models demonstrate AG reduces colon shortening, histological damage, and inflammatory cytokine expression. Clinical data include an RCT of AG in colorectal cancer surgery patients.

• L-glutamineScientific

  L-Glutamine is a conditionally essential amino acid that serves as a primary metabolic fuel for rapidly dividing cells including colonocytes. Multiple clinical trials confirm its role in supporting colonic mucosal integrity, reducing intestinal permeability, and supporting recovery from IBD and critical illness GI dysfunction.

• lactaseScientific

  When small intestinal lactase is insufficient, undigested lactose passes into the colon, where it is fermented by resident bacteria to produce short-chain fatty acids, hydrogen, methane, and carbon dioxide. This colonic fermentation is the proximate cause of all lactose intolerance symptoms, including bloating, flatulence, osmotic diarrhea, and cramping. Lactase supplementation acts upstream in the small intestine specifically to prevent lactose from reaching the colon.

• lactiplantibacillus plantarumScientific

  Lactiplantibacillus plantarum (renamed from Lactobacillus plantarum) is a clinically validated probiotic with RCT evidence for reducing IBS symptoms (abdominal pain, bloating) in the large intestine and modulating colonic microbiota. It is among the most studied probiotic strains for functional bowel disorders.

• lactobacillusScientific

  Lactobacillus species are well-characterized probiotic bacteria with documented effects on IBS symptoms, constipation, diarrhea, and colonic inflammation in multiple RCTs and systematic reviews. Though primarily small intestinal colonizers, many strains transit to and act in the large intestine.

• lactobacillus acidophilusScientific

  Lactobacillus acidophilus is a well-researched probiotic with documented benefits for colonic health including constipation relief, IBS symptom reduction, and protection against enteropathogens. It adheres to and colonizes intestinal epithelial cells in the large intestine.

• lactobacillus brevisScientific

  Lactobacillus brevis (Levilactobacillus brevis) is a heterofermentative probiotic that produces lactic acid, acetic acid, and GABA in the large intestine. It is found in fermented foods and has documented antimicrobial activity and immune-modulating effects in the GI tract.

• lactobacillus bulgaricusScientific

  Lactobacillus bulgaricus (Lactobacillus delbrueckii subsp. bulgaricus) is a classic yogurt bacterium with documented transit through and activity in the large intestine. Clinical evidence supports benefits for lactose maldigestion and restoration of gut microbiota balance after antibiotic-induced dysbiosis.

• lactobacillus caseiScientific

  Lactobacillus casei (Lacticaseibacillus casei) is a clinically studied probiotic benefiting large intestinal health, with evidence for reducing diarrhea, supporting UC remission, and modulating colonic microbiota composition in RCTs.

• lactobacillus delbrueckiiScientific

  Lactobacillus delbrueckii (including subsp. bulgaricus) is a classic yogurt culture with documented GI effects including reducing lactose maldigestion symptoms in the large intestine and contributing to colonic microbiome restoration. Clinical evidence primarily derives from yogurt RCTs.

• lactobacillus fermentumScientific

  Lactobacillus fermentum (Limosilactobacillus fermentum) is a heterofermentative probiotic producing lactic acid, acetic acid, and CO₂ in the large intestine. Clinical studies support its role in managing GI symptoms, reducing enteropathogens, and supporting colonic microbiota balance.

• lactobacillus gasseriScientific

  Lactobacillus gasseri is a native human GI colonizer with documented benefits for reducing abdominal fat, supporting bowel regularity, and modulating colonic microbiota. Clinical RCTs show benefits for obesity-related GI dysbiosis and colonic health.

• lactobacillus helveticusScientific

  Lactobacillus helveticus is a dairy probiotic bacterium with documented colonic health benefits including reduced inflammatory markers in IBD, improved stool consistency, and bioactive peptide production during GI transit that modulates colonic function.

• lactobacillus johnsoniiScientific

  Lactobacillus johnsonii is a native human GI colonizer that adheres to intestinal epithelial cells and inhibits pathogens including H. pylori. Clinical evidence supports its role in modulating colonic microbiota and reducing GI symptoms in IBS and constipation in combination probiotic preparations.

• lactobacillus kefiranofaciensScientific

  Lactobacillus kefiranofaciens is the primary producer of kefiran (the characteristic exopolysaccharide of kefir grains) in the large intestine environment and the dominant strain responsible for kefir's documented prebiotic and anti-inflammatory effects on colonic health.

• lactobacillus lactisScientific

  Lactobacillus lactis (Lactococcus lactis) is a lactic acid-producing bacterium found in fermented dairy products with documented colonic benefits including pathogen inhibition, production of bacteriocin nisin, and support of colonic microbiome balance. It has been studied in engineered forms for delivering anti-inflammatory molecules directly to the large intestine.

• lactobacillus paracaseiScientific

  Lacticaseibacillus paracasei is a probiotic with documented colonic health benefits including improved bowel function, inhibition of colonic pathogens, and anti-inflammatory effects in the large intestine. In vitro studies confirm strong adhesion to colonic epithelial cells and bile salt hydrolase activity.

• lactobacillus plantarumScientific

  Lactobacillus plantarum (Lactiplantibacillus plantarum) is a clinically validated probiotic for IBS, with the strain 299v shown to significantly reduce abdominal pain and bloating in IBS patients in clinical trials. It is also studied for UC and colonic microbiome restoration.

• lactobacillus reuteriScientific

  Lactobacillus reuteri (Limosilactobacillus reuteri) is a native human GI colonizer producing reuterin — an antimicrobial compound — in the gut. Clinical trials support its use for infantile colic, constipation, and diarrhea, with mechanisms operating through direct colonic effects on motility and inflammation.

• lactobacillus rhamnosusScientific

  Lactobacillus rhamnosus GG is one of the most extensively studied probiotic strains globally, with robust evidence for preventing and treating diarrhea, supporting IBS management, and protecting the colonic mucosal barrier. Multiple meta-analyses confirm its GI efficacy.

• lactobacillus salivariusScientific

  Lactobacillus salivarius (Ligilactobacillus salivarius) is a clinically studied probiotic with documented benefits for IBS and colonic inflammation, producing high levels of lactic acid and bacteriocins that inhibit pathogens in the large intestine.

• lactococcus caseiScientific

  Lactococcus casei (commonly described as Lacticaseibacillus casei, formerly Lactobacillus casei) is a clinically studied probiotic for colonic health including UC maintenance, constipation, and colorectal cancer prevention, with multiple RCT evidence.

• lactococcus lactisScientific

  Lactococcus lactis is a lactic acid bacterium that produces nisin (a potent bacteriocin against C. difficile and Listeria) and has been engineered for direct delivery of anti-inflammatory cytokines to the colonic mucosa. A Phase I clinical trial confirmed safety and reduced Crohn's disease activity.

• lactococcus rhamnosusScientific

  Lactococcus rhamnosus as listed likely refers to Lacticaseibacillus rhamnosus (formerly Lactobacillus rhamnosus), one of the most clinically documented probiotic strains for colon health including diarrhea prevention, IBS management, and colonic barrier protection.

• lactoferrinScientific

  Lactoferrin is an iron-binding glycoprotein from colostrum and milk with documented bifidogenic effects in the colon, antimicrobial activity against GI pathogens including C. difficile, and anti-inflammatory properties relevant to IBD. Clinical trials confirm its efficacy in reducing diarrhea incidence and colonic inflammation markers.

• lentinula edodes myceliaScientific

  L. edodes mycelia compounds—particularly lentinan, AHCC, LEM, and MSCE—demonstrate anti-inflammatory, antioxidant, and microbiota-modulatory effects in the large intestine in preclinical models. Clinical trials support their role as adjuvants improving prognosis in colorectal cancer patients.

• lignansScientific

  The large intestine is the primary site of lignan biotransformation: gut bacteria convert plant lignans to the bioactive enterolignans enterodiol and enterolactone. This conversion is essential for lignan bioactivity. Enterolignans are subsequently absorbed in the colon and enter hepatic portal circulation. Lignans have also shown antitumor effects in colorectal cancer cell lines.

• limoneneScientific

  D-limonene has been specifically studied in colonic disease models including ulcerative colitis and colorectal cancer cell lines. It suppresses colonic MMP-2/9, COX-2, PGE2, and NF-κB in UC models, reducing mucosal damage. In colorectal adenocarcinoma cells (Caco-2), it demonstrated antiproliferative activity via apoptosis induction and inflammatory pathway modulation.

• lion's maneScientific

  Lion's Mane polysaccharides reach the colon intact, where they are fermented by microbiota to produce SCFAs, selectively promote beneficial bacteria, reduce pathobionts, suppress colonic NF-κB inflammation, and maintain barrier integrity. Multiple animal IBD models and in vitro human fecal fermentation studies confirm these effects.

• luteolinScientific

  Luteolin is a flavone with documented anti-inflammatory and anti-cancer effects in the colon, inhibiting NF-κB and MAPK pathways in colonic tissue and colorectal cancer cells. Animal studies of colitis show significant improvements with luteolin, and it modulates the colonic microbiome.

• lycopeneScientific

  Lycopene is a carotenoid found in tomatoes with documented colorectal cancer chemopreventive activity. Epidemiological studies and clinical interventions show inverse associations between lycopene intake/serum levels and colorectal cancer risk, with mechanisms including antioxidant activity and inhibition of cancer cell proliferation in the colon.

• mangoScientific

  Mango's polyphenols and dietary fiber undergo extensive fermentation in the colon, producing short-chain fatty acids (SCFAs) and modulating the colonic microbiome. Human RCTs have documented favorable shifts in microbial composition and improved stool characteristics with mango consumption.

• millet seedScientific

  Millet's insoluble fiber is primarily fermented in the colon, producing SCFAs that nourish colonocytes and protect the colonic epithelium. Millet polyphenols reaching the colon modulate microbiota, upregulate tight junction proteins, and reduce colonic inflammation. High-fiber millet diets are associated with reduced colorectal cancer risk.

• monk fruitScientific

  Mogrosides from monk fruit pass unabsorbed through the small intestine and reach the colon intact, where they are fermented by resident microbiota into secondary mogrosides and short-chain fatty acids. The PMC 2021 in vitro study (PMC8495861) directly demonstrated this colonic metabolic interaction, including butyrate production that fuels colonocytes. TCM also documents monk fruit's intestine-moistening effects on the colon.

• mucinScientific

  The colon possesses one of the densest mucin layers in the body, composed primarily of MUC2 secreted by goblet cells, forming an inner (sterile) and outer (bacteria-colonized) mucus layer. Deficiency or structural abnormality of colonic mucin is directly linked to colitis, colorectal cancer susceptibility, and dysbiosis. Clinical biopsy studies and Muc2 knockout animal models establish this relationship definitively.

• myrrhScientific

  Myrrh has direct clinically-evidenced interactions with the colon, most notably through the Myrrhinil-Intest RCT demonstrating noninferiority to mesalazine in maintaining UC remission. Myrrh reduces colon inflammation and weight in animal colitis models and stabilizes the colonic epithelial barrier.

• N-acetyl-glucosamineScientific

  Rectal NAG administration and oral NAG have both been studied specifically in pediatric and adult IBD patients with colonic disease. Post-treatment biopsies showed reduced inflammatory infiltration, restoration of mucosal villi, and increased colonic GAG content. Murine DSS-colitis studies confirm NAG protects colon length and mucin-secreting areas.

• NAC (N-acetyl cysteine)Scientific

  NAC has clinical evidence for effects on colonic inflammation in IBD. A clinical trial in ulcerative colitis demonstrated significant improvements in colonic disease parameters and reduced pro-inflammatory cytokines. NAC's antioxidant effects on colonic mucosa oxidative stress have also been studied in experimental and clinical contexts.

• nopalScientific

  Nopal fiber ferments in the distal colon, documented by MRI studies measuring colonic volume and hydrogen breath tests. IBS RCTs demonstrate significant improvements in colonic symptom scores with 20 g/day nopal fiber. Animal studies show nopal increases colonic occludin protein (reducing gut permeability) and modifies cecal microbiota. Traditional use includes nopal for colitis and dysentery.

• oatScientific

  Oat β-glucan is fermented in the large intestine by colonic microbiota, generating short-chain fatty acids including butyrate that nourish colonocytes, enhance barrier function, and modulate local immune responses. Clinical studies confirm increased Lactobacillus, Bifidobacterium, and SCFA levels in the colon with oat intake.

• omega-3 fatty acidsScientific

  Omega-3 fatty acids have been studied for colorectal health, with epidemiological associations suggesting possible reduction in colon cancer risk, and emerging mechanistic evidence via gut microbiome modulation and anti-inflammatory prostaglandin pathways. The gut-brain axis research also implicates n-3 PUFAs in intestinal immune signaling.

• onionScientific

  Onion's prebiotic fructooligosaccharides are fermented in the colon to produce short-chain fatty acids (especially butyrate) that nourish colonocytes. Onion extract promotes SCFA production and beneficial microbial shifts in the colon in vitro. Quercetin and onion peel extracts also demonstrate anti-inflammatory effects on intestinal epithelial cells.

• ox bileScientific

  Bile acids that escape ileal reabsorption enter the colon, where they regulate mucosal secretion, motility via TGR5 receptors, and microbial ecology. Excess colonic bile acids drive secretory diarrhea; insufficient bile acid spillage is associated with slow transit. Ox bile supplementation can alter the quantity of bile acids reaching the colon, with relevant clinical effects on bowel habit.

• papayaScientific

  Papaya's fiber content supports colonic health by adding bulk, reducing transit time, and feeding beneficial microbiota. Clinical trial evidence shows papaya preparations reduce constipation in IBS and chronic digestive dysfunction. Papain also inhibits pathogenic bacteria associated with gut dysbiosis, which may benefit colonic microbial balance.

• peaScientific

  Pea fiber reaches the colon intact, serving as a substrate for fermentation by colonic microbiota. This fermentation produces SCFAs, increases microbial diversity, and supports colonocyte health. Animal studies show improved colonic microbiota and attenuated colonic tissue damage with pea fiber.

• peachScientific

  Peach leaves, flowers, and kernels all have pharmacologically supported laxative mechanisms targeting the large intestine. TCM classifies both peach fruit and kernel as entering the Large Intestine channel. Sakuranetin and multiflorin A are identified active laxative constituents.

• pearScientific

  Pear's pectin acts as a prebiotic in the colon, feeding beneficial bacteria and promoting butyrate production. Pear's sorbitol and insoluble fiber accelerate colonic transit and soften stool. Prospective cohort data specifically named apples/pears as associated with reduced diverticulitis risk — a colon disease — with a significant dose-response relationship.

• pectinScientific

  Pectin is a soluble prebiotic fiber from fruit cell walls that is fermented by colonic bacteria into short-chain fatty acids and has documented benefits for bowel health including diarrhea treatment in clinical trials. Modified citrus pectin has also been studied for colon cancer prevention and heavy metal detoxification via the colon.

• pediococcus acidilacticiScientific

  Pediococcus acidilactici is a lactic acid-producing probiotic with documented benefits for diarrhea prevention, particularly traveler's diarrhea, and modulation of colonic microbiota. It produces pediocin (a bacteriocin) active against Listeria and other colonic pathogens.

• pediococcus pentosaceusScientific

  Pediococcus pentosaceus is a lactic acid bacterium naturally found in fermented foods, with documented antimicrobial activity against colonic pathogens and evidence for modulating colonic microbiota and reducing GI inflammation in preclinical and early clinical studies.

• peppermintScientific

  Peppermint oil is the most clinically studied botanical for IBS (a large intestinal disorder), included in the 2021 American College of Gastroenterology IBS clinical guidelines. Multiple RCTs and meta-analyses confirm significant reductions in abdominal pain, bloating, and IBS symptom severity through menthol's smooth muscle relaxant effects on the colon.

• phellodendron amurenseScientific

  Berberine from P. amurense is an OTC drug in China for bacterial diarrhea and has demonstrated antimicrobial activity against colon-targeting pathogens including Shigella (dysentery), Vibrio cholerae, and Clostridium. Berberine modulates gut microbiota composition in the colon, increasing beneficial bacteria and short-chain fatty acid producers. P. amurense is indicated in TCM for 'damp-heat diarrhea and dysentery.'

• phosphatidylcholineScientific

  PC is the dominant phospholipid in colonic mucus, forming a protective hydrophobic barrier against luminal bacteria. UC patients show significantly depleted colonic mucosal PC. Delayed-release PC formulations targeting colonic delivery have demonstrated efficacy in multiple RCTs for active UC.

• plantagoScientific

  Plantago ovata (psyllium) has the most extensive clinical evidence base of any herbal fiber for colonic health: normalizing bowel movements, treating IBS, maintaining ulcerative colitis remission, reducing hemorrhoid symptoms, reducing diverticulosis risk, and acting as a prebiotic supporting colonic microbiota.

• plantainScientific

  Psyllium fiber from Plantago ovata acts primarily in the colon, generating SCFAs via bacterial fermentation, modulating microbiota composition in human clinical studies, maintaining colonic barrier integrity, and demonstrating efficacy in ulcerative colitis RCTs. P. major fiber ferments in the distal colon maintaining SCFA levels. These effects are supported by multiple human trials.

• pomegranateScientific

  Pomegranate ellagitannins are metabolized in the colon by gut bacteria to produce urolithins. Prebiotic activity supports beneficial colonic bacteria (Lactobacillus, Bifidobacteria). Clinical evidence includes improved clinical response in IBD patients and microbiome modulation in RCTs. Preclinical colitis models confirm pomegranate promotes mucosal healing.

• prickly pear cactusScientific

  Betalain-rich prickly pear extracts showed strong anti-inflammatory activity in human intestinal epithelial cells, matching or exceeding dexamethasone. An RCT at a nutrition conference found nopal fiber reduced IBS symptom severity. High fiber content supports colon motility and microbiota.

• propionic acidScientific

  The colon is the primary site of propionate production and action. Propionate is generated by colonic bacterial fermentation of dietary fibers and is rapidly absorbed by colonocytes. It maintains colonic mucosal barrier integrity, upregulates tight junction proteins, stimulates mucin production, drives enteroendocrine hormone release, and exerts local anti-inflammatory effects. Its actions on colonic L cells to release GLP-1 and PYY are foundational to its systemic metabolic effects.

• pruneScientific

  The colon is the primary site of prune's fermentable fiber and polyphenol activity. Sorbitol draws water into the colon for stool softening; pectin and other fibers undergo microbial fermentation producing SCFAs including butyrate that nourish colonocytes; and polyphenols shift the microbiome toward beneficial taxa. Multiple RCTs confirm accelerated colonic transit and improved stool formation.

• psylliumScientific

  Psyllium husk (Plantago ovata) is an FDA-recognized bulk-forming laxative with the strongest clinical evidence of any fiber for colon function. Randomized controlled trials show it significantly increases stool frequency and weight in chronic idiopathic constipation, and it is the only fiber recommended by the American College of Gastroenterology for both constipation and IBS. Its gel, arriving intact in the large intestine, normalizes stool form — softening hard stool and firming loose stool.

• quercetinScientific

  Quercetin is a widely studied polyphenol flavonol with documented anti-inflammatory effects on colonic tissue, prebiotic modulation of the colonic microbiome, and colorectal cancer chemopreventive properties demonstrated in multiple in vitro, animal, and early human studies.

• quinoaScientific

  Quinoa fiber reaches the colon where it undergoes fermentation by colonic bacteria, producing short-chain fatty acids (especially butyrate) that nourish colonocytes. Preclinical evidence shows quinoa diets prevent DSS-induced colitis and dysbiosis in murine models. Quinoa polysaccharides increase Bifidobacteria and Collinsella in fermentation studies, and butyrate production was consistently enhanced across 19 preclinical studies.

• radishScientific

  Radish fiber and glucosinolate metabolites influence colonic function and microbiota. In vitro fermentation studies show radish glucosinolates modulate colon microbiota from obese individuals. Radish leaves and roots provide dietary fiber supporting transit and colonic bulk. TCM also lists radish seed for treating constipation and diarrhea.

• resveratrolScientific

  Resveratrol is a polyphenol stilbene with documented anti-inflammatory and chemopreventive effects in the colon. The majority of orally consumed resveratrol reaches the large intestine, where it is metabolized by colonic bacteria and exerts direct effects on colonic mucosa relevant to IBD and colorectal cancer prevention.

• rhubarbScientific

  The colon is rhubarb's primary pharmacological target. Anthraquinones act on colonocytes to stimulate motility, alter water transport via aquaporin-3 inhibition, and modulate the colonic microbiome. EMA recognizes rhubarb for constipation, and RCTs confirm improvements in colonic transit, stool frequency, and microbiota composition.

• rhubarb rootScientific

  Rhubarb root (Rheum officinale/palmatum) contains sennosides and other anthraquinones that act as stimulant laxatives in the large intestine. It is used in both Traditional Chinese Medicine and Western herbal medicine to promote bowel movement and address constipation.

• rutinScientific

  Rutin (quercetin-3-O-rutinoside) is a flavonol glycoside fermented by colonic bacteria into quercetin and other bioactive metabolites. It has documented anti-inflammatory effects in colonic tissue and has been studied for colorectal cancer prevention and IBD management.

• ryeScientific

  The colon is the primary site of rye's beneficial activity: rye's dietary fiber is fermented by colonic microbiota to SCFA including butyrate, the main energy source for colonocytes. Clinical studies show rye increases stool frequency, raises fecal butyrate, and modulates microbial composition. Rye lignans may also reduce colon cancer risk by improving bowel function and reducing carcinogenic compounds.

• saccharomyces boulardiiScientific

  Saccharomyces boulardii is a probiotic yeast with robust clinical evidence for preventing and treating infectious diarrhea, C. difficile colitis, and IBS. RCTs confirm it reduces colonic permeability in Crohn's disease and improves quality of life in IBS patients through direct effects on the large intestinal mucosa.

• secoisolariciresinol diglucosideScientific

  The large intestine is both the primary site of SDG bioactivation (via bacterial conversion to enterodiol and enterolactone) and a target organ of SDG's anti-inflammatory effects. SDG protects colonic epithelial integrity, suppresses inflammatory cytokine expression, and modulates gut microbiota composition in high-fat diet mouse models. SDG counters oxidative stress in human colonic epithelial tissue in vitro.

• sennaScientific

  Senna is an FDA-approved OTC stimulant laxative whose active constituents (sennosides A and B) act specifically on the large intestine. The sennosides are metabolized by colonic flora into rhein-anthrone, which stimulates peristalsis and increases fluid secretion in the colon. It is listed on the WHO List of Essential Medicines and has been used medicinally since at least the 7th century AD.

• sennosidesScientific

  Sennosides are the active anthraquinone glycosides from Senna plants, specifically targeting the large intestine. They are prodrugs converted by colonic bacteria into rhein-anthrone, stimulating peristalsis and fluid secretion in the colon. Sennosides are included in official pharmacopeias and the WHO Essential Medicines List.

• sesameScientific

  An animal study (PMC) demonstrated sesame seed oil protected colonic histopathology, preserved mucus production, and normalized colonic immune markers in arsenic-exposed rats. Sesame's fiber content supports colonic microbiota and bowel regularity. In vitro studies show sesame lignans and oil inhibit colon malignant cell growth. Traditional use for intestinal health and constipation relief is well-documented.

• silymarinScientific

  Silymarin (the standardized flavonolignan extract of milk thistle) has documented anti-inflammatory and anti-cancer effects in colorectal tissue, inhibiting NF-κB and inducing apoptosis in colon cancer cells. Animal models of IBD show significant colitis reduction, and a clinical trial confirmed colon tissue penetration.

• sophoraScientific

  S. flavescens is specifically active in the large intestine via oxymatrine's documented effects on ulcerative colitis, a condition primarily affecting the mucosa and submucosa of the rectum and colon. Licensed TCM preparations for UC (which affects the colon) contain S. flavescens as primary ingredient.

• spinachScientific

  Spinach dietary fiber is fermented by colonic bacteria into short-chain fatty acids supporting colonocyte health. Spinach chlorophyll and antioxidants have been studied for potential anti-cancer effects in the colon, and spinach thylakoids in rat models modulate gut microbiota composition in the large intestine.

• SPMs (specialized pro-resolving mediators)Scientific

  The colonic mucosa produces SPMs during inflammatory episodes, with serum MaR1 and RvD1 documented as UC disease activity biomarkers in human patients. Ex vivo resolvin D2 treatment of colonic biopsies from IBD patients reduces cytokine production. SPMs restore colonic barrier function and promote mucosal healing.

• streptococcusScientific

  Streptococcus thermophilus, used in yogurt production, is documented to survive GI transit and produce lactase in the large intestine, reducing lactose maldigestion symptoms. As part of probiotic preparations, it is studied for colonic health maintenance and IBD management.

• streptococcus thermophilusScientific

  Streptococcus thermophilus is a classic yogurt culture documented to reduce lactose maldigestion symptoms in the large intestine and has been clinically studied in multi-strain probiotic preparations for ulcerative colitis. Multiple RCTs support its benefits for colonic health in the context of lactose intolerance and IBD.

• sulforaphaneScientific

  Sulforaphane activates Nrf2 in colonocytes to restore tight junction integrity, reduce colonic inflammation, reverse gut dysbiosis, and increase short-chain fatty acid production. Animal models of colitis consistently show protective effects. Human gut microbiome trials show SFN remodels colonic microbial networks.

• sweet wormwoodScientific

  Artemisinin and its derivatives have been studied extensively in rodent colitis models, with demonstrated reduction of colonic inflammation, cytokine levels, edema, and ulceration. The colon is a primary site of pharmacological action for these compounds in IBD research.

• tartarian asterScientific

  Aster tataricus extract has demonstrated preclinical activity relevant to intestinal motility. A PubMed-indexed 2021 study confirmed ATE relieved loperamide-induced constipation in mice by antagonizing muscarinic receptor binding of acetylcholine and inhibiting Ca²⁺ influx. In vitro, ATE modulated spontaneous and agonist-induced contractions of rat duodenal smooth muscle.

• terminaliaScientific

  T. chebula is documented as the primary purgative ingredient in Triphala and has a clinical trial confirming bowel-evacuating effects in constipated patients. An animal study found T. chebula ethyl acetate extract alleviated DSS-induced ulcerative colitis in mice through anti-inflammatory mechanisms. Traditional use for dysentery and diarrhea via astringent effects on the colon is well-established.

• thymoquinoneScientific

  Thymoquinone is the primary bioactive compound of Nigella sativa (black seed) with documented anti-inflammatory effects in the colon through NF-κB and COX-2 inhibition. Animal studies of colitis show significant reductions in colonic inflammation and mucosal damage.

• tributyrinScientific

  The colon is the primary site of tributyrin's bioactivity: it delivers butyrate directly to colonocytes, modulates colonic microbiota, preserves tight junctions, reduces colonocyte inflammation, and supports mucosal immune function. Tributyrin's formulation is specifically designed to maximize colonic butyrate delivery compared to sodium butyrate.

• triphalaScientific

  Triphala is an Ayurvedic polyherbal formula combining three fruits (Terminalia bellirica, Terminalia chebula, Emblica officinalis) with traditional and emerging scientific evidence for improving bowel regularity, reducing constipation, and modulating colonic microbiota. A clinical trial in GI disorder patients demonstrated reduction in constipation, abdominal pain, and bloating.

• turmericScientific

  Curcumin accumulates at high concentrations in the colon due to poor systemic absorption, enabling potent local anti-inflammatory, barrier-protecting, and microbiome-modulating effects. RCTs and meta-analyses confirm clinical benefit in ulcerative colitis. Evidence also supports effects on colorectal cancer prevention pathways, gut permeability, and microbiota composition.

• urolithin aScientific

  Urolithin A is a gut microbiota-derived metabolite of ellagitannins (from pomegranate, berries) produced exclusively in the colon. It has documented anti-inflammatory, anti-cancer (colorectal), and mitophagy-enhancing effects specifically in the large intestine, with clinical trials confirming its activity.

• wheatScientific

  The colon is the primary site of wheat fiber's physiological activity. Wheat bran increases stool bulk and accelerates transit in RCTs; arabinoxylan is fermented to SCFAs, supporting colonocyte energy and barrier function. Wheat bran polyphenols accumulate in the colon (90–95% not absorbed in small intestine) and modulate gut microbiota and mucosal inflammation.

• wheat grassScientific

  Wheatgrass has direct clinical evidence in the colon via its RCT-supported benefit in distal ulcerative colitis. Reviews document potential anti-inflammatory and antioxidant effects relevant to colorectal health. Wheatgrass administration during colon cancer chemotherapy supported immune parameters in a prospective trial.

• xylanaseScientific

  XOS produced by xylanase activity transit to the colon where they serve as preferred substrate for beneficial bacteria, driving SCFA fermentation and supporting colonic epithelial health. SCFA production lowers colonic pH, improves mineral absorption, and reduces the growth of pathogens. Animal studies show XOS reduce aberrant crypt foci in the colon and attenuate colonic inflammation. This pathway is well-documented in the peer-reviewed literature.

• xylooligosaccharidesScientific

  XOS is a well-documented colonic prebiotic: it resists digestion in the small intestine and is selectively fermented in the colon by Bifidobacterium. Multiple human clinical trials confirm its bifidogenic effect and improvements in stool frequency, consistency, and colonic microbiota composition in both healthy adults and those with functional constipation.

• yeastScientific

  Yeast beta-glucan and mannan-oligosaccharides (MOS) from S. cerevisiae cell walls pass undigested to the large intestine where they are fermented by resident microbiota, selectively promoting Bifidobacterium and Lactobacillus growth. S. boulardii modulates colonic immune responses and reduces inflammation in multiple colonic conditions including antibiotic-associated diarrhea and IBD.

• zeoliteScientific

  The large intestine is a primary site for zeolite clinoptilolite's anti-diarrheal and microbiome-modulatory effects. Clinical studies in IBS-D and chronic diarrhea patients document normalization of stool consistency and reduced colonic inflammation. Animal data show zeolite alleviates colitis-associated microbial dysbiosis. Reduction of colonic ammonia load and pathogenic bacteria are proposed mechanisms.

• activated charcoalTraditional

  Activated charcoal (oral activated charcoal, OAC) adsorbs gases, toxins, and chemicals in the GI lumen, including the large intestine, reducing flatulence and bowel symptoms. It has been used clinically for over 200 years for GI toxin adsorption and as an OTC remedy for intestinal gas.

• alliinTraditional

  Alliin is the stable precursor amino acid in intact garlic cloves that is enzymatically converted to allicin upon garlic tissue disruption. Its GI health significance is as the source of allicin's documented antimicrobial and anti-inflammatory effects in the large intestine, with centuries of traditional garlic use for bowel infections.

• artichokeTraditional

  Artichoke (Cynara scolymus) leaf extract is used traditionally and in modern herbal medicine for digestive symptoms. It contains inulin (prebiotic fructan) and cynarin/cynaropicrin that promote bile flow and digestive function, with documented effects on reducing IBS-like symptoms in clinical studies.

• bacillus indicusTraditional

  Bacillus indicus HU36 is a spore-forming probiotic strain producing carotenoids in the GI tract, used traditionally in Ayurvedic fermented preparations. Some sources associate it with colon health, but standalone human RCT evidence for large intestinal effects is limited; its use is primarily traditional/naturopathic.

• bayberryTraditional

  Bayberry is documented for colitis and large intestinal inflammation in traditional medicine, and the flavonoid myricetin (present in bayberry) has been studied in animal models for colonic inflammation prevention. The astringent tannins are the primary mechanism for intestinal anti-inflammatory effects.

• belleric myrobalanTraditional

  Belleric myrobalan has deep traditional applications for the large intestine, including use as a laxative (promoting bowel movements), treatment of constipation, and as a bowel tonic. Gaia Herbs' traditional monograph describes it as a restorative tonic to the bowels. The tannin content and antispasmodic properties are relevant to colonic function. Hemorrhoids (affecting the rectum/anal canal) are also traditionally addressed.

• biota seedTraditional

  The Large Intestine is one of three meridians biota seed enters in TCM, and 'moistening the intestines and freeing the bowels' is one of its two primary traditional actions. The seed's high oil content is the proposed mechanism for lubricating the colon and easing dry, hard stools. This is one of the most consistently documented traditional applications across classical herbals.

• black seedTraditional

  Black seed (Nigella sativa) has been used for over 2,000 years in Islamic, Ayurvedic, and Middle Eastern traditional medicine for GI complaints including constipation, diarrhea, abdominal pain, and intestinal parasites. Thymoquinone (the primary bioactive) shows anti-inflammatory effects in colonic tissue.

• black walnutTraditional

  Black walnut (Juglans nigra) hulls have been used in North American and European folk medicine for centuries as a remedy for intestinal parasites and digestive disturbances attributed to the large intestine. Juglone (a naphthoquinone) is the primary bioactive with anthelmintic and antimicrobial properties. Clinical RCT evidence specifically for the large intestine is lacking.

• brevibacillus laterosporusTraditional

  Brevibacillus laterosporus is a soil-derived spore-forming bacterium used as a probiotic supplement, traditionally associated with promoting intestinal health by inhibiting pathogenic microorganisms in the gut. Limited clinical evidence exists; its use for colon health is primarily based on traditional/historical naturopathic use.

• cape aloeTraditional

  Cape aloe (Aloe ferox) is a southern African plant whose latex (bitter aloe) contains anthraquinone glycosides used traditionally as a stimulant laxative acting in the large intestine, similar to Aloe vera latex. It is used in European herbal products and recognized by Commission E.

• cat's clawTraditional

  Cat's Claw (Uncaria tomentosa) has centuries of traditional use by Amazonian indigenous peoples for GI conditions including intestinal inflammation, colitis, and dysbiosis. Its oxindole alkaloids and quinovic acid glycosides have documented anti-inflammatory effects, with limited clinical evidence for IBD.

• chamomileTraditional

  Chamomile (Matricaria chamomilla) has centuries of traditional use in European herbalism as a GI antispasmodic, carminative, and anti-inflammatory agent for the intestines, including the colon. The German Commission E has a positive monograph for chamomile for GI spasms and inflammatory diseases of the GI tract.

• collagenTraditional

  Collagen peptides and hydrolyzed collagen have traditional use for gut health and are studied for supporting the integrity of the colonic mucosal barrier. Preclinical and limited clinical evidence suggests collagen peptides may support intestinal permeability and mucosal healing in the large intestine.

• coptis chinensisTraditional

  Coptis chinensis (Huang Lian) is a foundational Traditional Chinese Medicine herb used specifically for conditions attributed to 'intestinal heat,' including diarrhea, dysentery, and colonic inflammation. Its primary bioactive, berberine, has documented effects on large intestinal function. Traditional use is supported by emerging scientific evidence through berberine research.

• dandelionTraditional

  Dandelion (Taraxacum officinale) has been used traditionally in European and Chinese herbal medicine as a digestive tonic, mild laxative, and prebiotic source (containing inulin) to support bowel regularity and colonic microbiota. Commission E recognizes dandelion for disturbances of bile flow and digestive complaints.

• european elderTraditional

  Elderberry has documented traditional use as a mild laxative affecting the large intestine, recorded from Hippocrates through the EMA. In vitro studies show elderberry extract protects colonic mucosal cells from oxidative damage. Traditional use as a laxative/detoxifier is the primary basis of this relationship.

• goldensealTraditional

  Goldenseal (Hydrastis canadensis) is a North American herbal remedy containing berberine used traditionally by Native Americans for intestinal inflammation, diarrhea, and GI infections. Its berberine content provides the primary documented colon activity including antimicrobial and anti-inflammatory effects in the large intestine.

• kombuchaTraditional

  Kombucha is a traditional fermented tea beverage containing live microorganisms, organic acids, and polyphenols associated with digestive health. Traditional use for gut support is longstanding; emerging laboratory evidence suggests effects on colonic microbiota and gut barrier, though human RCT evidence remains limited.

• lactobacillus kefiriTraditional

  Lactobacillus kefiri is a heterofermentative lactic acid bacterium unique to kefir with antimicrobial properties and traditional association to the digestive health benefits of kefir. Evidence for its specific role in large intestinal health is primarily from in vitro studies and kefir-as-whole-product clinical trials.

• lactobacillus parakefiriTraditional

  Lactobacillus parakefiri is a lactic acid bacterium isolated from kefir grains with traditional association to fermented milk's gut health benefits. It produces antimicrobial compounds in the GI tract and is part of the kefir microbiome associated with colon health through traditional use of kefir.

• lactobacillus pentosusTraditional

  Lactobacillus pentosus (Lactiplantibacillus pentosus) is a heterofermentative lactic acid bacterium found in fermented olives and vegetables with traditional association to digestive health. In vitro evidence confirms antimicrobial activity against colonic pathogens, though standalone human RCT evidence for large intestinal conditions is limited.

• leuconostocTraditional

  Leuconostoc species are heterofermentative lactic acid bacteria naturally present in fermented vegetables (kimchi, sauerkraut) with traditional association to digestive health. They produce lactic acid, acetic acid, and bacteriocins (leucocins) with antimicrobial activity against colonic pathogens, though standalone human RCT evidence for colon health is limited.

• marshmallowTraditional

  Marshmallow root (Althaea officinalis) produces mucilaginous polysaccharides that coat and soothe the GI mucosa, including the colon. The European Medicines Agency (EMA) has issued a Community Herbal Monograph for marshmallow root for irritation of the oral and pharyngeal mucosa, and traditional use for GI soothing is well-documented in ESCOP and Commission E.

• milk thistleTraditional

  Milk thistle (Silybum marianum) and silymarin are primarily hepatoprotective, but have some evidence for reducing GI inflammation. Traditional use for GI conditions including intestinal spasms is documented in Commission E. Limited but emerging evidence for colonic protective effects through anti-inflammatory and antioxidant mechanisms.

• myrobalanTraditional

  The colon is the primary traditional organ target of TC in Ayurvedic medicine. TC is described as supporting the 'proper function of the colon' through its laxative, prokinetic, and astringent properties, and is the primary component of Triphala — Ayurveda's foremost colon-cleansing formula.

• nattokinaseTraditional

  Nattokinase is a serine protease enzyme produced by Bacillus subtilis natto during fermentation. While primarily studied for cardiovascular effects (fibrinolysis), it has traditional association with gut health through its origin in natto — a fermented food long used in Japan for digestive wellness. Direct colon health evidence is limited.

• okraTraditional

  Okra (Abelmoschus esculentus) pods produce a mucilaginous fiber-rich gel that coats and soothes the colonic mucosa, supporting bowel regularity and providing a prebiotic substrate for colonic bacteria. Traditional use in African and Asian medicine for GI complaints including constipation and diarrhea is documented.

• oreganoTraditional

  Oregano has traditional documented use for colitis and large intestinal infections in Mediterranean and Asian folk medicine. Its antimicrobial activity against enteric pathogens and anti-inflammatory properties provide mechanistic support. Oregano's carminative and antidiarrheal traditional indications relate primarily to large bowel function. Human clinical trial evidence for colonic endpoints is absent.

• paw pawTraditional

  Carica papaya is used traditionally across tropical regions for intestinal parasite infections, constipation, and colon cleansing. Papaya seeds and latex contain anthelmintic compounds active against intestinal worms, and papain promotes digestive transit. Clinical evidence for antiparasitic effects in the intestinal tract is emerging, though evidence specific to the colon as opposed to the broader digestive tract is largely traditional.

• propolisTraditional

  Bee propolis has traditional use across multiple cultures as an antimicrobial and anti-inflammatory agent for GI conditions including intestinal parasites and inflammatory bowel conditions. Flavonoids and phenolic acids in propolis show in vitro antimicrobial activity against colonic pathogens, with limited but emerging clinical evidence for IBD.

• slippery elmTraditional

  Slippery elm (Ulmus rubra) bark produces mucilage that coats and soothes the intestinal wall, including the colon. Traditionally used by Native Americans for GI ailments, it has been suggested as beneficial in IBD based on antioxidant effects, though robust clinical RCT evidence remains limited.

• slippery elm barkTraditional

  Slippery elm bark is traditionally used for its mucilaginous properties that coat and protect the colonic mucosa. Native American and early Western herbalism have long applied it for diarrhea, constipation, and intestinal inflammation, with emerging research supporting potential anti-inflammatory activity in IBD.

• stillingiaTraditional

  Stillingia was used as a cathartic and laxative affecting the large intestine, with documented use for constipation in Native American, southern US folk medicine, and Eclectic traditions. In large doses it acts as a drastic purgative. No clinical evidence exists.

• trichosanthesTraditional

  Trichosanthis Fructus is attributed to the large intestine meridian in TCM, with classical indications including bowel lubrication for constipation, relief of dry stools, and treatment of hematochezia and dysentery in Korean classical medicine. Seeds are specifically used for constipation at doses up to 20 g. Evidence is pharmacopoeial and traditional.

• uncariaTraditional

  Uncaria (Cat's Claw, U. tomentosa) is used traditionally by Amazonian peoples for GI inflammatory conditions including intestinal inflammation and colitis. Its alkaloids and glycosides have anti-inflammatory activity in colonic tissue, with preliminary clinical evidence for UC.